title: [New facts of long-term prophylaxis for bipolar affective disorder].
abstract: Lithium and with restrictions, carbamazepine, valproic acid, lamotrigine, olanzapine, aripiprazole and quetiapine, are approved in Germany for maintenance treatment of bipolar disorder. Lithium is the only drug that (I) proved to be effective for the prevention of depressive as well as manic episodes in state-of-the-art studies without an enriched design and that (II) is approved for the maintenance treatment of bipolar disorders without restrictions. It (III) is also the only drug which is recommended for maintenance treatment by the current German S3 guidelines on bipolar disorders with the highest degree of recommendation (A) and (IV) is the only drug with a well proven suicide preventive effect. Hence, lithium is the mood stabilizer of first choice. No patient should be deprived of lithium without a specific reason. Side effects and risks are manageable if both the physician and the patient are well informed. Detailed and practical information on a safe use of lithium can be found in the S3 guidelines on bipolar disorders. For patients who do not respond sufficiently to lithium, have contraindications or non-tolerable side effects, other mood stabilizers should be used. Restrictions in their respective approval as well as specific side effects and risks have to be taken into account. Because maintenance treatment is a long-term treatment, particular concern should be paid to drugs with the potential risk of a metabolic syndrome, particularly atypical antipsychotics.
authors.affiliation: Abteilung für Psychiatrie, Schlosspark-Klinik, Heubnerweg 2, 14059, Berlin, Deutschland, bschor@schlosspark-klinik.de.
authors.forename: T
authors.initials: T
authors.lastname: Bschor
authors.forename: B
authors.initials: B
authors.lastname: Müller-Oerlinghausen
authors.forename: G
authors.initials: G
authors.lastname: Stoppe
authors.forename: C
authors.initials: C
authors.lastname: Hiemke
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000517:prevention & control*; D019317:Evidence-Based Medicine; D005858:Germany; D006801:Humans; D018020:Lithium Compounds / Q000008:administration & dosage* / Q000592:standards*; D009462:Neurology / Q000592:standards*; D017410:Practice Guidelines as Topic; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D018020:Lithium Compounds